AMN
Serum Institute of India has entered into a new landmark partnership with Gavi and the Bill & Melinda Gates Foundation to accelerate the production of up to 100 million doses of COVID-19 vaccines for India and other low and middle income countries.
In a statement, World largest vaccine manufacturer Serum Institute of India said, it is important to make sure that the most remote and poorest countries of the world have access to affordable cure and preventive measures to contain the Covid-19 pandemic.
It said, through this association, the company will ramp up the efforts to save the lives of millions of people from this dreadful disease.
In the new arrangement, Serum Institute of India will get the funding from the Gates foundation through international vaccine alliance GAVI. The funding will provide support to vaccine maker for potential vaccines candidate from AstraZeneca and Novavax.
Company has set an affordable ceiling price of 3 dollar per dose. Earlier, Serum Institute of India had bagged a contract with British drugmaker AstraZeneca to supply one billion doses of Oxford University’s potential COVID-19 vaccine. Recently, American Company Novavax has entered a supply and license agreement with the Serum Institute of India for the development and commercialisation of its COVID-19 vaccine candidate.
